Corvus Pharmaceuticals, Inc.
CRVS
$15.97
$0.161.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 62.51% | 7.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.77% | 15.56% | |||
| Operating Income | -21.77% | -15.56% | |||
| Income Before Tax | -11.13% | -21.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.13% | -21.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.13% | -21.31% | |||
| EBIT | -21.77% | -15.56% | |||
| EBITDA | -21.79% | -15.62% | |||
| EPS Basic | -2.42% | -21.13% | |||
| Normalized Basic EPS | -2.48% | -21.15% | |||
| EPS Diluted | -2.42% | -21.13% | |||
| Normalized Diluted EPS | -2.48% | -21.15% | |||
| Average Basic Shares Outstanding | 8.48% | 0.15% | |||
| Average Diluted Shares Outstanding | 8.48% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||